Session (CTI)

Separate registration required.

The reliance on data from electronic medical records (EMR) still predominantly demonstrates the effectiveness of health technologies. However, in the era of digital transformation, new data sources emerge, potentially serving as complementary or alternative sources of real-world evidence (RWE). Digital health platforms (DHPs), including wearables, mobile applications, and phone cameras, represent a burgeoning class of healthcare solutions. They not only offer novel avenues for healthcare platforms but also stand as potential sources of evidence for assessing the effectiveness of pharmaceuticals, medical devices, and healthcare services. Are we prepared to embrace digital solutions as standard healthcare platforms and as new sources of effectiveness data?

This course will initially introduce participants to various types of digital solutions, explore critical aspects of value assessment, and delve into how DHPs can constitute a fresh source of RWE applicable for pricing and reimbursement decision making. Through preselected case studies encompassing pharmaceuticals and medical devices, participants will examine practical methodologies for leveraging digital solutions as sources of RWE across diverse countries and healthcare systems. Interactive discussions will engage participants in considering the integration of innovative data sources into healthcare decision making, while accounting for varied stakeholder perspectives. The overarching objective is to advocate for the inclusion of data collected by DHPs in health economics and outcomes research.

Moreover, the course aims to stimulate discourse on adapting economic evaluation methods to effectively capture the complexities associated with adopting DHPs (such as intervention complexity, outcome complexity, and causal pathway complexity) as the new frontier of RWE.

In this course, participants will familiarize themselves with different types of digital solutions, consider critical aspects of value assessment, and finally how and in which therapeutic areas they can constitute a new source of RWE applicable for pricing and reimbursement decision making. The course will discuss the advantages/disadvantages of including data collected by DHPs into health economics and outcomes research and will recommend/demonstrate how methods of economic evaluation might be adapted to better capture the complexity associated with the adoption of DHPs as the new source of RWE.